Gastroenterology
Volume 137, Issue 2 , Pages 412-415 , August 2009

Do Diabetes Drugs Modify the Risk of Pancreatic Cancer?

  • Yu–Xiao Yang

      Affiliations

    • Corresponding Author InformationReprint requests Address requests for reprints to: Yu-Xiao Yang, MD, MSCE, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, 722 Blockley Hall, 423 Guardian Drive, Philadelphia, Pennsylvania 19104-6021

  • Image Result

    (A) Diabetes mellitus, metformin, exogenous insulin and pancreatic cancer. IGF-I, insulin-like growth factor-I; AMPK, AMP-activated protein kinase. (B) Proposed mechanism of actions of metformin on AM

    (A) Diabetes mellitus, metformin, exogenous insulin and pancreatic cancer. IGF-I, insulin-like growth factor-I; AMPK, AMP-activated protein kinase. (B) Proposed mechanism of actions of metformin on AMPK and pancreatic cancer. AMPK, AMP-activated protein kinase; mTOR, mammalian target of rapamycin.

 Conflicts of interest The author discloses no conflicts.

PII: S0016-5085(09)00991-3

doi: 10.1053/j.gastro.2009.06.022

Gastroenterology
Volume 137, Issue 2 , Pages 412-415 , August 2009

Article Tools

* Image Usage & Resolution